VisionGate has received financial backing from Dignity Health in Arizona for development of a revolutionary, non-invasive test for the early detection of lung cancer, the world’s deadliest cancer. Patient sputum samples are processed on the company’s patented Cell-CT® system – aptly named because it takes an optical CT scan of individual cells to generate digital, high-resolution, 3D images of each cell for early disease diagnosis, rare cell detection and research.
The investment aligns with Dignity Health’s commitment to provide patients with one of the most advanced lung disease programs in the Southwest through its Norton Thoracic Institute at Dignity Health St. Joseph’s Hospital and Medical Center.
“We are committed to bringing the most innovative advancements in health care to our patients,” President and CEO of Dignity Health, Arizona Service Area Linda Hunt said. “VisionGate has a very promising technology.”
VisionGate’s wholly owned clinical laboratory in Phoenix will provide analytical services using the Company’s LuCED® lung cancer test based on sputum (phlegm) samples from patients who collect three morning coughs at home. Published clinical data demonstrates a high degree of accuracy in detecting early stage lung cancer with few to no false positives. LuCED will be added to the Thoracic Institute’s lung cancer screening program as part of a formal clinical trial.
Dignity Health’s investment will support VisionGate’s goal to commercialize LuCED and make it available to the public in 2015 through the launch of the VisionGate Biosignatures Laboratory (VBL) headed by VisionGate’s President, Scarlett Spring.
“It is critically important to have the potential of our technology confirmed by an esteemed organization like Dignity Health,” VisionGate CEO Alan Nelson, PhD, said. “With support from Dignity Health, the Phoenix area will emerge as the epicenter for improving the lives of patients at risk of lung cancer.”